Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Fluoxetine effective against premature ejaculation, but compliance remains poor

04 Dec 2019

Despite the efficacy of fluoxetine in producing clinical improvements in premature ejaculation, adherence beyond 6 months remains low, a recent study has shown.

The study included 130 men (mean age, 31±14 years) with primary premature ejaculation, who used fluoxetine and had at least 12 months of follow-up data. Self- and partner-reported variables were used to assess the efficacy of the intervention. Medication adherence was also set as an outcome.

At baseline, 94 percent reported poor ejaculatory control and 72 percent had partners who were under moderate or severe distress due to the premature ejaculation; almost half (47 percent) of the participating men had the similar distress.

After 3 months, 76 percent reported improvements of at least 1 minute in the intravaginal ejaculatory latency time (IELT), while 64 percent, 38 percent and 11 percent reported improvements of at least 2, 3 and 5 minutes, respectively. Continued use of fluoxetine at 6 and 12 months led to sustained IELT improvements of at least 1 minute in 72 percent and 69 percent, respectively.

Significantly fewer men self-reported having poor ejaculatory control at the same time point (94 percent to 42 percent; p<0.01). Similarly, severe personal (45 percent to 11 percent) and partner (70 percent to 27 percent; p<0.01 for both) distress rates also dropped significantly.

Despite such improvements, adherence was low. At 3 months, 11 percent of the participants had dropped out of the treatment. This shot up to 56 percent and further to 72 percent by months 6 and 12, respectively.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.